What is Flex Pharma?
Flex Pharma, Inc. operates as a specialized biotechnology firm headquartered in Boston, focusing on the treatment of muscle cramps and spasms linked to neurological conditions and physical exertion. The company maintains a unique operational structure divided into two primary segments: Consumer Operations and Drug Development. Its consumer-facing brand, HOTSHOT, provides a beverage solution for exercise-associated muscle cramps, distributed through direct-to-consumer e-commerce channels. Simultaneously, the firm is advancing its clinical research, most notably with its lead candidate FLX-787. This transient receptor potential ion channel activator is currently undergoing exploratory Phase 2 clinical trials to address complex conditions such as multiple sclerosis and amyotrophic lateral sclerosis, demonstrating the company's dual focus on immediate market revenue and long-term therapeutic innovation.
How much funding has Flex Pharma raised?
Flex Pharma has raised a total of $86.4M across 1 funding round:
Stock Offering
$86.4M
Stock Issuance/Offering (2015): $86.4M, investors not publicly disclosed
Key Investors in Flex Pharma
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Flex Pharma?
With the recent influx of capital, Flex Pharma is poised to scale its clinical development efforts for FLX-787, moving toward critical milestones in its Phase 2 trials. The strategic allocation of these funds will likely prioritize the expansion of its drug development pipeline, potentially broadening the therapeutic applications for its ion channel activator technology. Furthermore, the company is expected to leverage its consumer segment to sustain operational cash flow, providing a stable foundation for the high-risk, high-reward nature of its pharmaceutical research. Investors will be closely monitoring the progression of its clinical data, as successful outcomes could significantly enhance the company's valuation and market influence in the neurology sector.
See full Flex Pharma company page
